Effective management necessitates the use of anti-diabetic and anti-obesity therapies that do not compromise leukemia control; glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown promise in achieving weight loss while improving glycemic control [15]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.